Medical expert of the article
New publications
Preparations
Encoder
Last reviewed: 23.04.2024
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Encorat prevents the development of seizures that occur in various forms of epilepsy. The drug does not lead to the suppression of respiratory activity, and in addition it does not affect the renal and cardiac function and does not change the temperature. Effectively prevents the appearance of complex, simple, as well as secondary seizures of the generalized type.
Valproate Na is the main active element of the drug; it increases GABA indices inside the brain and postsynaptic nerves. The anticonvulsant effect of the drug is also developed by influencing the movement of potassium ions through neural walls.
Indications Enkorata
It is used in the treatment of epilepsy, which has a partial or generalized form (in the case of atonic, myoclonic or tonic-clonic seizures, as well as absences).
It may also be prescribed in the case of special syndromes in which the development of seizures (SLH or West syndrome) is observed.
Release form
The release of the therapeutic substance is produced in tablets (volume of 0.2 or 0.3 g), which are packed in strips of 10 pieces. Inside the box - 10 such strips.
Antarctica
Encorate chrono is produced in tablets with a volume of 0.2 g - 10 pieces inside the strip; inside packs - 3 such strips. In addition, it is sold in tablets with a volume of 0.3 or 0.5 g - 10 tablets inside the strip; inside the box - 1 or 3 such strips.
Pharmacodynamics
Encorate is an anticonvulsant whose principle of influence is associated with the slowing down of the action of the GABA transferase enzyme, as well as with an increase in GABA values within the CNS. As a result, there is a weakening of convulsive readiness and excitability of motor cerebral areas. At the same time, the medication improves the mood and mental state of patients.
Valproic acid can overcome the placenta and BBB, and in addition it is released during lactation with mother's milk.
Pharmacokinetics
Absorption.
When used orally, plasma Cmax values are recorded after 1-4 hours. Therapeutic plasma values are 300-600 mmol / l. The level of bioavailability is 96-100%.
Distribution processes.
The level of protein synthesis is 78-94%.
Exchange processes.
Valproate Na is involved in intrahepatic metabolism through glucuronidation, and in addition, α- and β-oxidation.
Excretion.
The drug is excreted through the kidneys. The term half-life is in the range of 6-16 hours, and the level of clearance is in the range of 6-27 ml / hour / kg. Small indicators of valproate Na are excreted with mother's milk.
Dosing and administration
The medication is taken orally - tablets are swallowed without chewing, along with food. During the day, take the medicine 1-2 times.
An adult should be administered 1-2 times a day for 300-600 mg of drug. In this case, the dosage is gradually increased (1-fold over a 3-4-day period); while it should increase to a maximum of 2.4 g per day.
For a child weighing less than 40 kg, the drug is prescribed in a daily dose of 20 mg / kg; if weighing more than 40 kg - 40 mg / kg.
Cancel the medication should be gradually, periodically reducing the dosage. This period lasts for 1-2 years.
[9]
Use Enkorata during pregnancy
Do not use Encorat during pregnancy.
If it is required to use medication for HB, then breastfeeding for the period of therapy should be abandoned.
Contraindications
The main contraindications:
- administration to persons allergic to valproic acid and the elements contained in the composition of the medication;
- porphyria;
- hemorrhagic diathesis;
- severe stages of diseases affecting the pancreas and liver;
- leukocytopenia or thrombocytopenia.
Caution is required when used in case of kidney or bone marrow dysfunction, childhood oligophrenia, congenital type enzymopathies, cerebral diseases, liver or pancreas abnormalities, and hypoproteinemia.
Side effects Enkorata
At the initial stage of therapy, temporary conditions can be noted: increased appetite, vomiting, abdominal pain, diarrhea and anorexia.
When using tablets, irritability, lethargy, tremors, headaches, ataxia and changes in mood or behavior may occur. In addition, there is dysarthria, anemia, enuresis, visual disturbances, problems with consciousness and an increase in the size of the mammary glands. There is also an increase in the activity of intrahepatic enzymes, allergy (alopecia, an exudative form of erythema with a malignant character, urticaria, photosensitivity, rashes and angioedema), leuco- or thrombocytopenia, blood clotting disorders and platelet aggregation. In addition, secondary type amenorrhea or dysmenorrhea, peripheral edema, hyperammonemia or -creatinemia, a decrease in fibrinogen values, an increase in bilirubin blood parameters and a change in weight (increase or decrease) occur.
Occasionally, Encorata causes depression, hallucinations, stupor, aggressiveness or psychosis, and in addition, obstipy, bleeding, hemorrhages of the petechial type, hematomas, galactorrhea or coma. Fatal pancreatitis is also possible.
A single injection of the drug leads to the development of the fulminant form of hepatitis with a fatal outcome.
Interactions with other drugs
The drug potentiates the medicinal activity of other anticonvulsants (phenytoin with lamotrigine), MAOI, anxiolytics, thymoleptics with ethyl alcohol, indirect anticoagulants, as well as antiplatelet agents.
Combining medication and clonazepam can provoke an absence status to a severe degree.
The drug increases blood parameters of primidone and barbiturates.
In the case of a combination with the drug, the lamotrigine excretion slows down.
Neuroleptic tranquilizers as well as MAOIs weaken the therapeutic effect of Encorata, lowering the convulsive threshold.
The effectiveness of the drug is enhanced when combined with salicylates.
The introduction of the drug along with carbamazepine, phenobarbital or mefloquine reduces the blood level of valproic acid.
The use of drugs and myelotoxic substances increases the likelihood of developing bone marrow dysfunction.
When combined with felbamate, the blood levels of Encorata increase, due to which the dosage of the latter must be reduced.
Storage conditions
Encorate should be stored in a dry and dark place, with temperature indicators no higher than + 25 ° C.
Shelf life
Encorate can be used within a 36-month term from the date the therapeutic substance is sold.
Application for children
The drug is not used in persons younger than 3 years.
[18]
Analogs
Analogues of the medication are the drugs Gabapentin, Bifren and Tiaprid with Lamotrigine, and besides Gababamma, Tison with Finlepsin, Convalis and Fezipam with Neurontin, as well as Elzepam, Lamolep with Falylepsin and Rivotril. In addition, the list includes Convulsan and Gopantam, Nitrazepam and Toreal.
Attention!
To simplify the perception of information, this instruction for use of the drug "Encoder" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.
Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.